Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases

8 Pages Posted: 18 Apr 2023

See all articles by Daniel T. Michaeli

Daniel T. Michaeli

Heidelberg University - National Center for Tumor Diseases

Thomas Michaeli

Heidelberg University - Department of Personalized Oncology

Date Written: April 17, 2023

Abstract

This cross-sectional study compares Medicare & Medicaid spending on and beneficiaries of ultra-rare, rare, common, and non-orphan cancer drugs.

Note:
Funding Information: No funding was received for conducting this study.

Conflict of Interests: The authors declare that they have no conflicts of interest.

Keywords: orphan designation; cancer drug; healthcare expenditure; common orphans; rare orphans; ultra-rare orphans

JEL Classification: I1;I10;I13;I18

Suggested Citation

Michaeli, Daniel T. and Michaeli, Thomas, Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases (April 17, 2023). Available at SSRN: https://ssrn.com/abstract=4421181 or http://dx.doi.org/10.2139/ssrn.4421181

Daniel T. Michaeli (Contact Author)

Heidelberg University - National Center for Tumor Diseases ( email )

Germany

Thomas Michaeli

Heidelberg University - Department of Personalized Oncology ( email )

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
44
Abstract Views
247
PlumX Metrics